The Union government had made an advance payment of Rs 1,500 crore in June 2021 for reserving 30 crore doses. Biological E, a Hyderabad-based vaccine manufacturer, on Monday received emergency use authorisation (EUA) from India’s drug regulator for their Covid-19 vaccine for the 12 to 18-year age group. The Drugs Controller General of India (DCGI) … Read more
The company said it has reached production levels of 75 million doses per month at present and would make 100 plus million doses per month from February 2022. Hyderabad-based Biological E said on Tuesday that it would deliver the 300 million doses of the Covid-19 vaccine, Corbevax, as promised to the government of India. Corbevax … Read more
“The approvals from the DCGI will encourage us to move forward and produce the Covid-19 vaccine to meet the country’s vaccination needs. These approvals will help support subsequent filings with the World Health Organisation as well,” Bio E MD Mahima Datla. Biological E has received approval from the Drugs Controller General of India (DCGI) to … Read more
Biological E’s vaccine – a RBD protein sub-unit vaccine – is currently undergoing Phase-3 clinical trials after showing promising results in phases 1 and 2. The government will make an advance payment of Rs 1,500 crore to Biological E for reserving 300 million vaccine doses. These vaccine doses will be manufactured and stockpiled by Biological … Read more